Navigation Links
Replidyne Terminates Faropenem Agreements
Date:6/23/2008

LOUISVILLE, Colo., June 23 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) today announced that it has decided to terminate its license agreement with Asubio Pharma Co., Ltd. for faropenem medoxomil (faropenem). In conjunction with this decision, the Company also announced that it has terminated its supply agreement with Asubio Pharma Co., Ltd. and Nippon Soda Co. Ltd. for production of faropenem. These decisions were made as a result of the Company being unable to secure a partner for the faropenem program. As previously announced, Replidyne had discontinued clinical development of faropenem pending the outcome of discussions with potential partners for the program.

As a result of today's decision, the Company expects to incur charges of up to Japanese Yen 440 million (approximately $4.1 million), consisting of a license termination fee of up to Japanese Yen 375 million (approximately $3.5 million) to Asubio Pharma Co., Ltd. and the reimbursement of engineering costs under its supply agreement of up to Japanese Yen 65 (approximately $0.6 million) to Nippon Soda Co. Ltd. Replidyne will also pay Nippon Soda Co. Ltd. Japanese Yen 99 million (approximately $0.9 million) for delay compensation related to the period from January 1, 2008 through the termination of its supply agreement.

"We are clearly disappointed that we have been unable to identify a partner for the faropenem program," stated Kenneth J. Collins, President and Chief Executive Officer of Replidyne. "We have decided to terminate this program in order to preserve cash and focus our attention on our previously discussed strategic initiatives and our C. difficile Infection (CDI) program and novel anti-infective programs based on DNA replication inhibition tec
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Replidyne to Report First Quarter 2008 Earnings
2. Replidyne Announces 2007 Fourth Quarter and Full Year Results
3. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
4. Replidyne to Announce Third Quarter 2007 Earnings
5. CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
6. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
7. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
8. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
9. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
10. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
11. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... of what happens on the surface of cells. The ... A group of researchers from Lund University in Sweden ... a large number of vertical nanowires, known as a ... cell and its surroundings takes place through the cell ... the cell together and that largely comprises lipids, built ...
(Date:9/2/2014)... AVENTURA, Fla. , Sept. 2, 2014  Technology ... has announced that its wholly-owned subsidiary Renuell Int,l, Inc. ... National Aeronautics and Space Administration ("NASA") at the Johnson ... See photos: tapplic.com/houstonphotos/ ... stated, "We are very pleased to announce our latest, ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
(Date:9/2/2014)... , September 2, 2014 Culot ... research and lab management services  BioData, producer ... is pleased to announce the appointment of Louis ... recently served as VP Marketing and Business Development at ... research and clinical applications. Previously, Culot worked ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Louis Culot Appointed as BioData's CEO 2
... ... Delay, LEXINGTON, Mass., ... Glenn L. Cooper,MD, its chairman and chief executive officer is postponing his,previously-announced ... of the recent delay in the approval of NEBIDO(R)., Dr. Cooper ...
... Raymond J. De,Hont, Chairman and Chief Executive Officer ... Fybroc business unit has received,an order for approximately $500,000 ... second and third quarters of the Company,s current fiscal ... order Fybroc has received this year from the,Eastern European ...
... Cell Therapeutics, Inc.,(Nasdaq and MTA: CTIC) today announced that ... million, newly issued 15% Convertible,Senior Notes due 2011, with ... warrant to purchase approximately 14.6 million shares of common ... This transaction constitutes a partial exercise of a previously ...
Cached Biology Technology:Indevus Announces Management Changes 2Indevus Announces Management Changes 3Indevus Announces Management Changes 4Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 2Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 3Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 2
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... study published in the September issue of ... a novel strategy to diagnose the leading cause ... structural damage has occurred. This advance involves quantifying ... the endothelium of retinal vessels. Using new probes ... the early molecular development of diabetic retinopathy. , ...
(Date:9/2/2014)... Best-selling author Sam Kean stops by Reactions this ... 50-foot super shark that, despite what "Shark Week" may ... about it at http://youtu.be/KhFygIoW_MA . , Kean,s book, ... Love and the History of the World from the ... treatment in a 10-episode video series produced for the ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... optogenetics, the researchers are able to target one cell ... to find out exactly what goes wrong in the ... Prof. Dr. Stefan Herlitze (RUB Department for Biology and ... Biological Chemistry . The Bochum team examined a specific ...
... MD FASEB MARC (Minority Access to Research Careers) ... 2011 Society for Leukocyte Biology (SLB) Meeting in Kansas ... are meant to promote the entry of underrepresented minority ... basic science community and to encourage the participation of ...
... - Researchers speaking on the final day of the 6th ... 2011) have focused on the growing interest in the scientific ... have been growing over the past 12 months and are ... Society (IAS) convened working group concentrating its initial efforts on ...
Cached Biology News:Controlling movements with light 2 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 2 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 3 Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health 4
... polyclonal to Neuron navigator 1 ( Abpromise ... Synthetic peptide conjugated to KLH derived from ... Neuron navigator 1. (Note: the amino acid ... as ab32208 .) Entrez ...
Na+/H+ exchanger, isoform NHE1....
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
Biology Products: